Prof. Dr. Florian Bassermann

Medical Degrees

• Medical Graduation — Studies in Ulm, Munich, and New York
• Doctorate (Dr. med./DM) — Technical University of Munich (TUM), Germany, 2002
• Board Certification — Internal Medicine and Hematology/Oncology, Germany
• Postdoctoral Teaching Qualification (Habilitation) — TUM, Germany
• Tenure Track Professorship — TUM, 2015

Fellowships & Special Training

• Postdoctoral Research Fellowship — New York University (NYU), USA, 2006–2009
• Emmy Noether Junior Research Group Leader — German Research Foundation (DFG), 2009
• Specialist Training in Internal Medicine — TUM Klinikum rechts der Isar
• Specialist Training in Hematology and Oncology — TUM Klinikum rechts der Isar

Certifications & Accreditations

• German Medical Association (Bundesärztekammer) Registration
• Board-Certified Specialist — Internal Medicine and Hematology/Oncology (Bavaria)
• Full Professor — Technical University of Munich

Major Conditions Treated

• Acute Myeloid Leukemia (AML)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Myeloid Leukemia (CML)
• Chronic Lymphocytic Leukemia (CLL)
• Multiple Myeloma
• Hodgkin & Non-Hodgkin Lymphoma
• Mantle Cell Lymphoma
• B-Cell Malignancies
• Myelodysplastic Syndrome (MDS)
• Lung Cancer
• Gastrointestinal (GI) Cancers
• Anemia & Bleeding Disorders

Sub-specialties

• B-Cell Malignancies & Acute Leukemias: Personalised molecular therapy, immunotherapy, and cellular therapies — a hematologist specialist in Munich, Germany for cancer patients worldwide.
• Stem Cell Transplantation: Autologous, allogeneic, and umbilical cord blood transplantation for hematological malignancies.
• Translational Cancer Research: Heads working group at TranslaTUM (TUM Central Institute for Translational Cancer Research); leads DFG-funded TRR 387 "UbiQancer" transregional collaborative research center since 2024.
• Precision Oncology: Tumor genomics, functional proteomics, and targeted therapy for hematologic and solid tumors — for international patients seeking best hematology treatment in Germany.
• Molecular Pathophysiology of Malignancies: Research on ubiquitin-dependent signaling pathways, cell cycle regulation, DNA damage response, and cell metabolism.

Advanced Procedures & Treatments

• Autologous Stem Cell Transplantation
• Allogeneic Stem Cell Transplantation
• Umbilical Cord Blood Transplantation
• CAR-T Cell Therapy
• Precision Oncology / Molecular Therapy
• Immunotherapy (Monoclonal Antibodies, Checkpoint Inhibitors)
• Bispecific Antibody Therapy
• Chemotherapy Protocols for Hematologic Malignancies
• Bone Marrow Biopsy & Genetic Analysis
• Clinical Trial Enrolment in Novel Therapies

Current Affiliation

• Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Str. 22, 81675 Munich, Germany — Director, Department of Internal Medicine III (Hematology / Oncology), 2017–Present
• TranslaTUM (TUM Central Institute for Translational Cancer Research) — Head of Working Group, Cell Biology of Cancer, Present
• TRR 387 "UbiQancer" (DFG-Funded Transregional Collaborative Research Centre) — Head / Principal Investigator, Since 2024

Past Affiliations

• TUM Klinikum rechts der Isar — Tenure Track Professor, 2015–2017
• TUM Klinikum rechts der Isar — Senior Physician, 2011–2015
• TUM Klinikum rechts der Isar — Assistant Physician / Emmy Noether Group Leader, 2009–2011
• New York University (NYU), Department of Pathology — Postdoctoral Research Fellow, 2006–2009

Academic & Research Roles

• Full Professor of Internal Medicine — Technical University of Munich (TUM)
• Director — Department of Internal Medicine III, TUM Klinikum rechts der Isar
• Principal Investigator — DFG Transregional Research Centre TRR 387 "UbiQancer"
• Member — Professorial Faculty, TUM School of Medicine and Health
• Member — Researcher Database, German Cancer Consortium (DKTK)
• Author — 223+ peer-reviewed publications

Key Achievements

• 23+ years of clinical and research experience
• Director of a major German University Hospital Hematology-Oncology department since 2017
• 223+ peer-reviewed publications including landmark papers in Cell, Nature Medicine, Nature Cell Biology, Science, and Nature
• ERC Consolidator Grant recipient (2015)
• Theodor Frerichs Prize (DGIM, 2015)
• Walther Flemming Medal (DGZ, 2010)
• Emmy Noether Program (DFG, 2009)
• Leader of a flagship DFG Transregional Research Centre on cancer ubiquitin signaling

National & International Awards

• ERC Consolidator Grant — European Research Council, 2015
• Langener Science Award — 2015
• Theodor Frerichs Prize — German Society of Internal Medicine (DGIM), 2015
• Walther Flemming Medal — German Society of Cellular Biology (DGZ), 2010
• Emmy Noether Program — German Research Foundation (DFG), 2009

Professional Memberships

• German Society of Hematology and Medical Oncology (DGHO) — Active Member
• German Society of Internal Medicine (DGIM)
• German Society of Cellular Biology (DGZ)
• German Cancer Consortium (DKTK) — Researcher
• German Research Foundation (DFG) — Collaborative Research Centre Leader
• Technical University of Munich — Professorial Faculty

Published Papers (Selected)

• Eichner R, Heider M, Fernández-Sáiz V et al., Bassermann F. "Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity." Nature Medicine. 2016;22:735–743.
• Baumann U, Fernandez-Saiz V, Rudelius M et al., Bassermann F. "Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis." Nature Medicine. 2014;20(12):1401–1409.
• Fernández-Sáiz V, Targosz BS, Lemeer S et al., Bassermann F. "SCF-Fbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma." Nature Cell Biology. 2013;15(1):72–81.
• Bassermann F, Frescas D, Guardavaccaro D et al. "The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint." Cell. 2008;134(2):256–267.
• Busino L, Bassermann F, Maiolica A et al. "SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins." Science. 2007;316:900–904.
• Frescas D, Guardavaccaro D, Bassermann F et al. "The histone demethylase JHDM1B is a nucleolar protein that represses transcription of ribosomal RNA genes." Nature. 2007;450:309–313.
• Bassermann F, von Klitzing C, Munch S et al. "NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry." Cell. 2005;122:45–57.
• 223+ peer-reviewed publications in total.

Ongoing Research & Clinical Interests

• Ubiquitin-dependent signaling in malignant diseases (TRR 387 "UbiQancer")
• B-cell malignancies and acute leukemia biology
• Mantle cell lymphoma treatment-induced evolution
• Multiple myeloma molecular mechanisms
• Lung and GI cancer translational research

*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.